Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model

Long-acting antiretroviral agents for preexposure prophylaxis (PrEP) represent a promising new alternative to daily oral regimens for HIV prevention. Lenacapavir (LEN) is a first-in-class long-acting capsid inhibitor approved for the treatment of HIV-1 infection. Here, we assessed the efficacy of LE...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekerman, Elena, Yant, Stephen R., VanderVeen, Laurie, Hansen, Derek, Lu, Bing, Rowe, William, Wang, Kelly, Callebaut, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425210/
https://www.ncbi.nlm.nih.gov/pubmed/37384413
http://dx.doi.org/10.1172/JCI167818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425210/
https://www.ncbi.nlm.nih.gov/pubmed/37384413
http://dx.doi.org/10.1172/JCI167818

Ejemplares similares